May 25, 2016 | News Release Review

News release uses restraint in describing early results of experimental cancer drug. Good.

How do you describe an experimental cancer drug without losing balance? This release teeters a bit but ends up making the stick.

4 Star

Investigational CDK4/6 inhibitor abemaciclib is active against a range of cancer types

May 24, 2016 | Story Review

CBS News story hypes unproven stem cell treatment for spinal cord injury

This story effectively conveys the devastation of spinal cord injuries and correctly identifies stem cell therapy as an experimental and unproven treatment, but its thrust that the therapy “shows promise” is misleading; its efficacy has yet to be supported by rigorous trials.

2 Star

Experimental procedure aimed at repairing spinal cord shows promise

May 24, 2016 | Story Review

New surgical method for uterine fibroids gets thorough look by Inquirer

The story relies heavily on an anecdote, tracking one patient’s experience with the experimental procedure, but provides a good overview of the surgical treatment options available for women with uterine fibroids.

4 Star

Doctors test new device for uterine fibroids

May 24, 2016 | Story Review

Except for presidential anecdote, NBC story on new melanoma drug was well-balanced

By including a discussion of costs, harms, and alternatives, readers are left with a pretty good idea of what this new intervention is about.

5 Star

Cancer Drug Keytruda Keeps Some Patients Alive For 3 Years

Toolkit

Tips for Understanding Studies

View More

Toolkit

Story Reviews

Our team of reviewers applies 10 standardized criteria to news stories that include claims about health care interventions. ~2,000 reviews published.

Read More

News Release Reviews

We systematically evaluate the quality of health care-related news releases by journals, medical centers, drug/device makers, others.

Read More

Blog

Wide-ranging exploration of issues in journalism, journal publishing, health care PR, advertising and marketing. Some opinions - publisher Gary Schwitzer's & others'.

Read More